IS THERE A FUTURE FOR ALLERGEN IMMUNOTHERAPY IN THE CURRENT MEDICAL ENVIRONMENT?

Abstract

Introduction

It is 113 years since the first report of efficacy of Allergen Immunotherapy was published. Since then, there have been many changes to this treatment which have led to increased costs for the dispensing allergist with lagging increases in reimbursement. In this study everyday costs and reimbursement were compared to actual data and receipts generated in a Manhattan allergy practice. .

Methods

Actual costs from invoices over a 12 month period were tabulated and costs of materials used in patient extract preparations were calculated, Both obvious as well as hidden costs were considered and will be listed. . Actual reimbursement as well as Medicare reimbursement rates as published by CMS were compared. Factors which influence the market were considered.

Results

When comparing maintenance therapy with reimbursement, at least in Manhattan, there is almost no excess from current reimbursement rates indicating little or no profit. There is a significant variability in insurance compensation and rules for delivering immunotherapy.

Conclusion

Allergen immunotherapy, considering rising costs of material, labor and overhead is in danger of becoming unfeasible in the near future. Adding governmental regulation, and insurance regulatory practices suggest allergists may need to change scope of practice as well as the need to strongly support Allergy Advocacy measures.